Immunohistochemical Expression of CD24 and Its Correlation with Clinicopathological Features in Malignant Surface Epithelial Tumors of the Ovary
Keywords:
Ovarian cancer, Surface epithelial tumors, CD24, Intratumoral heterogeneity, Cancer stem cells (CSCs)Abstract
Background: Surface epithelial ovarian cancer (EOC) is the deadliest gynecological malignancy, mainly due to late-stage diagnosis and therapeutic resistance. Intratumoral heterogeneity, driven by cancer stem cells (CSCs), contributes to metastasis, recurrence, and therapy resistance. Cluster of Differentiation 24 (CD24) has emerged as a promising biomarker linked to tumor progression, metastasis, and immune evasion, but further research is needed to understand its role in ovarian cancer progression and patient outcomes.
Aim: This study investigates the immunohistochemical expression of CD24 in malignant surface epithelial ovarian tumors and its correlation with clinicopathological parameters and patient outcomes.
Methods: We performed a retrospective cohort analysis involving 117 formalin-fixed, paraffin-embedded (FFPE) samples of malignant ovarian surface epithelial tumors, retrieved from the archives of the Surgical Pathology Laboratory at our University oncology center in the period between 2018 and 2021. Patients underwent surgical resection, with follow-up data collected until 2024. Immunohistochemical (IHC) staining for CD24 was performed, and expression levels were assessed based on staining percentage and intensity. The correlation between CD24 expression and clinicopathological factors, disease-free survival (DFS), and overall survival (OS) was analyzed using appropriate statistical methods, including Kaplan-Meier survival analysis and Cox regression.
Results: CD24 expression was observed in 61.5% of cases, with varying expression levels: low (17.9%), moderate (23.1%), and high (20.5%). High CD24 expression was predominantly observed in HGSC (p=0.02) and was significantly associated with advanced FIGO stage (p=0.001), high tumor grade (p=0.001), lymph node involvement (p=0.001) and positive peritoneal-omental cytology (p=0.001). Univariate analysis revealed that patients with high CD24 expression exhibited significantly shorter DFS (p=0.001) and OS (p=0.001), compared to those with lower or absent expression. Cox regression identified CD24 as a significant predictor of shorter disease-free survival (p=0.001), while its role in overall survival showed a non-significant trend (p=0.499), suggesting a prognostic value that requires further validation.
Conclusion: CD24 overexpression in surface epithelial ovarian cancer is associated with aggressive tumor behavior, advanced stage, and worse survival outcomes. These findings suggest that CD24 expression may contribute to prognostic assessment in ovarian cancer. Further studies are needed to confirm its role and explore the potential of CD24-targeted therapies.
Downloads
References
Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet (London, England). 2019;393(10177):1240-53.
Peres LC, Cushing-Haugen KL, Köbel M, et al. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. Journal of the National Cancer Institute. 2019;111(1):60-8.
Romani C, Capoferri D, Grillo E, et al. The Claudin-Low Subtype of High-Grade Serous Ovarian Carcinoma Exhibits Stem Cell Features. Cancers. 2021;13(4).
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA: a cancer journal for clinicians. 2023;73(1):17-48.
Casey L, Khan MYA. Serous Tumors of the Ovary. In: van Krieken JHJM, editor. Encyclopedia of Pathology. Cham: Springer International Publishing; 2020. p. 1-12.
Motohara T, Yoshida GJ, Katabuchi H. The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance. Seminars in cancer biology. 2021; 77:182-93.
Nakamura K, Terai Y, Tanabe A, et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways. Oncology reports. 2017;37(6):3189-200.
Zhao K, Wu C, Li X, et al. From mechanism to therapy: the journey of CD24 in cancer. Frontiers in immunology. 2024; 15:1401528.
Landen CN, Jr., Goodman B, Katre AA, et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Molecular cancer therapeutics. 2010;9(12):3186-99.
Chen GY, Tang J, Zheng P, et al. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science (New York, NY). 2009;323(5922):1722-5.
Kleinmanns K, Fosse V, Bjørge L, et al. The Emerging Role of CD24 in Cancer Theranostics-A Novel Target for Fluorescence Image-Guided Surgery in Ovarian Cancer and Beyond. Journal of personalized medicine. 2020;10(4).
Association WM. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191-4.
Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. The American journal of surgical pathology. 2004;28(4):496-504.
Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2021;155 Suppl 1(Suppl 1):61-85.
Nagare RP, Sneha S, Sidhanth C, et al. Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours. Cancer biomarkers: section A of Disease markers. 2020;28(3):397-408.
Gu Y, Zhou G, Tang X, et al. The biological roles of CD24 in ovarian cancer: old story, but new tales. Frontiers in immunology. 2023; 14:1183285.
Jang Y, Kang S, Han HH, et al. CD24 induced cellular quiescence-like state and chemoresistance in ovarian cancer cells via miR-130a/301a-dependent CDK19 downregulation. Cell Death Discovery. 2024;10(1):81.
Gu Y, Zhou G, Tang X, et al. The biological roles of CD24 in ovarian cancer: old story, but new tales. Frontiers in immunology. 2023;14.
Kim S, Park JM, Park S, et al. Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR. Journal of Experimental & Clinical Cancer Research. 2023;42(1):292.
Fang X, Zheng P, Tang J, et al. CD24: from A to Z. Cellular & molecular immunology. 2010;7(2):100-3.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
